Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

Table 3 Cost-utility analysis of compared strategies based on different Brands in the first-line treatment of HR + / HER2- MBC

Strategy	Cost ($)	Incr Cost^b($)	Eff	Incr QALYs^b	ICER^b ($/QALY)
Letrozole (Iranian Brands)^a	7,453.69		2.861
Letrozole (Foreign Brands)	7,531.34	77.65	2.861	0.000	(undefined)
Palbociclib (Iranian Brand) + Letrozole	14,839.08	7,385.39	3.403	0.543	13,609
Palbociclib (Foreign Brand 2) + Letrozole	58,403.04	50,949.35	3.403	0.543	93,887
Palbociclib (Foreign Brand 1) + Letrozole	82,041.04	74,587.35	3.403	0.542	137,445
Ribociclib + Letrozole	96,247.45	88,793.76	3.597	0.736	120,583

ISSN: 2191-1991